Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the diabetes control and complications trial

Diabetes

Volumn 52, Issue 10, 2003, Pages 2623-2629

  Purnell, Jonathan Q ^a   Dev, Raj K ^b   Steffes, Michael W ^c   Cleary, Patricia A ^d   Palmer, Jerry P ^b   Hirsch, Irl B ^b   Hokanson, John E ^e   Brunzell, John D ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; GLUTAMATE DECARBOXYLASE 65; INSULIN; INSULINOMA ASSOCIATED PROTEIN 2; LIPID; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HUMAN; HYPOGLYCEMIA; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIA; ISOENZYMES; LIPIDS; MALE; MEDICAL RECORDS; WEIGHT GAIN;

EID: 0141866833     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.10.2623     Document Type: Article

References (45)

1. The DCCT Research Group: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 11:567-573, 1988
2. Wing RR, Klein R, Moss SE: Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes. Diabetes Care 13:1106-1109, 1990
3. The Diabetes Control and Complications Trial Research Group: Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 24:1711-1721, 2001
4. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the Diabetes Control and Complications Trial. JAMA 280:140-146, 1998
5. Kissebah AH, Vydelingum N, Murray RW, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254-260, 1982
6. Kaplan NM: The deadly quartet, upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989
7. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. Obesity Res 2:364-371, 1994
8. Brunzell JD, Hokanson JE: Dyslipidemia of central obesity and insulin resistance. Diabetes Care 22 (Suppl. 3):C10-C13, 1999
9. Shuman WP, Newell-Morris LL, Leonetti DL, Wahl PW, Moceri VM, Moss AA, Fujimoto WY: Abnormal body fat distribution detected by computed tomography in diabetic men. Invest Radiol 21:483-487, 1986
10. Gautier JF, Mourier A, de Kerviler E, Tarentola A, Bigard AX, Villette JM, Guezennec CY, Cathelineau G: Evaluation of abdominal fat distribution in noninsulin-dependent diabetes mellitus: relationship to insulin resistance. J Clin Endocrinol Metab 83:1306-1311, 1998
11. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE: Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 273:E425-E432, 1997
12. Ganda OP, Soeldner JS, Gleason RE: Alterations in plasma lipids in the presence of mild glucose intolerance in the offspring of two type II diabetic parents. Diabetes Care 8:254-260, 1985
13. Laws A, Stefanick ML, Reaven GM: Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:343-347, 1989
14. Osei K, Cottrell DA, Orabella MM: Insulin sensitivity, glucose effectiveness, and body fat distribution pattern in nondiabetic offspring of patients with NIDDM. Diabetes Care 14:890-896, 1991
15. Martin BC, Warram JH, Rosner B, Rich SS, Soeldner JS, Krolewski AS: Familial clustering of insulin sensitivity. Diabetes 41:850-854, 1992
16. Schumacher MC, Maxwell TM, Wu LL, Hunt SC, Williams RR, Elbein SC: Dyslipidemias among normoglycemic members of familial NIDDM pedigrees. Diabetes Care 15:1285-1289, 1992
17. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41:1575-1586, 1992
18. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM: Insulin resistance in offspring of hypertensive parents. BMJ 307:92-96, 1993
19. Stewart MW, Humphries DB, Benish TS, Barriocanal LA, Trajano LR, Alberti KG, Walker M: Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care 18:1020-1022, 1995
20. Barnett AH, Eff C, Leslie RD, Pyke DA: Diabetes in identical twins: a study of 200 pairs. Diabetologia 20:87-93, 1981
21. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD: Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 30:763-768, 1987
22. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 125:177-188, 1994
23. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
24. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
25. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, Petersen JS, Boel E, Dyrberg T, Lemmark A: Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 91:368-374, 1993
26. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362, 1993
27. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R, the UK Prospective Diabetes Study Group: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes (UKPDS 25). Lancet 350:1288-1293, 1997
28. Hawa MI, Fava D, Medici F, Deng YJ, Notkins AL, De Mattia G, Leslie RD: Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 23:228-233, 2000
29. The DCCT Research Group: Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 10:1-19, 1987
30. DCCT Manual of Operations. Springfield, VA, U.S. Department of Commerce, National Technical Information Service, 1993
31. National Institutes of Health: The Lipid Research Clinics Population Studies Data Book: The Prevalence Study. Vol. 1. Washington, DC, DHHS Government Printing Office, 1980
32. The Diabetes Control and Complications Trial Research Group: Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 46:1829-1839, 1997
33. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
34. The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 35:530-545, 1986
35. The DCCT Research Group: Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 33:2267-2271, 1987
36. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
37. Capell WH, Zambon A, Austin MA, Brunzell JD, Hokanson JE: Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 16:1040-1046, 1996
38. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111, 1999
39. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP: Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 50:1008-1013, 2001
40. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22:39-47, 1998
41. Comuzzie AG, Allison DB: The search for human obesity genes. Science 280:1374-1377, 1998
42. Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagnon YC, Bouchard C: The human obesity gene map: the 2001 update. Obes Res 10:196-243, 2002
43. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M, O'Rahilly S, Frayling TM, Bell JI, Lathrop GM, Bennett A, Dhillon R, Fletcher C, Groves CJ, Jones E, Prestwich P, Simecek N, Rao PV, Wishart M, Bottazzo GF, Foxon R, Howell S, Smedley D, Cardon LR, Menzel S, McCarthy MI: A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 69:553-569, 2001
44. Terry RB, Wood PDS, Haskell WL, Stefanick ML, Krauss RM: Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. J Clin Endocrinol Metab 68:191-199, 1989
45. Brunzell JD, Chait A: Diabetic dyslipidemia: pathology and treatment. In Ellenberg and Rijkin's Diabetes Mellitus. 5th ed. Porte D, Sherwin J, Eds. Norwalk, CT, Appleton and Lange, 1997, p. 1077-1098